The modulating actions of sulfonylurea on atrial natriuretic peptide release in experimental acute heart failure

被引:16
作者
Chen, HH
Oh, KY
Terzic, A
Burnett, JC
机构
[1] Mayo Clin & Mayo Fdn, Cardiorenal & Cardiovasc Res Labs, Div Cardiovasc Dis, Dept Med, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Cardiorenal & Cardiovasc Res Labs, Div Cardiovasc Dis, Dept Physiol, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Cardiorenal & Cardiovasc Res Labs, Div Cardiovasc Dis, Dept Pharmacol, Rochester, MN 55905 USA
关键词
ATP-sensitive K+ channel; Kir6.2; cardioprotection; kidney; natriuresis; sulfonylurea;
D O I
10.1016/S1388-9842(99)00074-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: This study defined the modulating actions of sulfonylurea on acute release of atrial natriuretic peptide (ANP) in experimental acute heart failure. Background: Sulfonylurea drugs, blockers of cardioprotective ATP-sensitive K+ (K-ATP) channels, may increase the risk of early cardiovascular mortality. In cardiovascular diseases such as acute heart failure, early release of ANP is essential for cardiorenal homeostasis. Although K-ATP channels regulate secretion of hormones, such as insulin, it is unknown whether sulfonylureas interfere with ANP release in acute heart failure. Methods: The effects of acute administration of glyburide (0.3 mg/kg), a prototype sulfonylurea, on ANP release and sodium excretion were measured in vivo in a canine model of pacing-induced acute heart failure characterized by acute atrial stretch. Immunoreactivity, in atrial tissue, for ANP and the K-ATP channel subunit, Kir6.2, was determined using specific antibodies. Results: With increased left atrial pressure in heart failure, plasma levels of ANP increased rapidly and peaked within 25 +/- 3 min. Glyburide delayed the time required for peak plasma ANP secretion to 48 +/- 5 min. This resulted in reduced natriuresis from 84 +/- 17 mu Eq/min in the absence of glyburide, to 34 +/- 9 mu Eq/min in the presence of glyburide. However, glyburide did not alter the renal natriuretic responsiveness to exogenously administered ANP in normal dogs. In atrial tissue, both ANP and the K-ATP channel subunit, Kir6.2, displayed strong immunoreactivity and co-localization. Conclusions: Glyburide delays release of ANP in acute heart failure resulting in impaired natriuresis. This cannot be ascribed to an antinatriuretic effect on the kidney, but rather may be due to interference with K-ATP channel-dependent ANP secretion from the atrium. Such adverse outcome of sulfonylurea drug use could reduce the compensatory capacity to preserve cardiorenal homeostasis in acute heart failure. (C) 2000 European Society of Cardiology. All rights reserved.
引用
收藏
页码:33 / 40
页数:8
相关论文
共 36 条
[1]   THE SULFONYLUREA RECEPTOR [J].
ASHCROFT, SJH ;
ASHCROFT, FM .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1175 (01) :45-49
[2]   Dual effect of glyburide, an antagonist of K-ATP channels, on metabolic inhibition-induced Ca2+ loading in cardiomyocytes [J].
Brady, PA ;
Zhang, SC ;
Lopez, JR ;
Jovanovic, A ;
Alekseev, AE ;
Terzic, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 308 (03) :343-349
[3]   The sulfonylurea controversy: More questions from the heart [J].
Brady, PA ;
Terzic, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (05) :950-956
[4]  
Brady PA, 1998, CIRC RES, V82, P272
[5]   ATRIAL-NATRIURETIC-PEPTIDE ELEVATION IN CONGESTIVE-HEART-FAILURE IN THE HUMAN [J].
BURNETT, JC ;
KAO, PC ;
HU, DC ;
HESER, DW ;
HEUBLEIN, D ;
GRANGER, JP ;
OPGENORTH, TJ ;
REEDER, GS .
SCIENCE, 1986, 231 (4742) :1145-1147
[6]  
CLARK MA, 1993, J PHARMACOL EXP THER, V265, P933
[7]   Association and stoichiometry of K-ATP channel subunits [J].
Clement, JP ;
Kunjilwar, K ;
Gonzalez, G ;
Schwanstecher, M ;
Panten, U ;
AguilarBryan, L ;
Bryan, J .
NEURON, 1997, 18 (05) :827-838
[8]  
Cleveland JC, 1997, CIRCULATION, V96, P29
[9]   ATRIAL STRETCH, NOT PRESSURE, IS THE PRINCIPAL DETERMINANT CONTROLLING THE ACUTE RELEASE OF ATRIAL NATRIURETIC FACTOR [J].
EDWARDS, BS ;
ZIMMERMAN, RS ;
SCHWAB, TR ;
HEUBLEIN, DM ;
BURNETT, JC .
CIRCULATION RESEARCH, 1988, 62 (02) :191-195
[10]   Sulfonylurea K-ATP blockade in type II diabetes and preconditioning in cardiovascular disease - Time for reconsideration [J].
Engler, RL ;
Yellon, DM .
CIRCULATION, 1996, 94 (09) :2297-2301